Published in Presse Med on June 01, 2010
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27
Treatment of pulmonary arterial hypertension. N Engl J Med (2004) 6.88
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation (2010) 5.87
Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med (2013) 4.98
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol (2002) 4.79
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98
Pulmonary arterial hypertension in patients treated by dasatinib. Circulation (2012) 2.87
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Chronic thromboembolic pulmonary hypertension. Circulation (2006) 2.58
Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.52
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 2.48
New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure. Chest (2004) 2.47
Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest (2009) 2.40
Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J (2006) 2.34
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension. Eur Respir J (2012) 2.32
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med (2015) 2.23
CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med (2002) 2.15
C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2011) 2.12
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med (2007) 2.03
Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation (2011) 1.92
Severe pulmonary hypertension during pregnancy: mode of delivery and anesthetic management of 15 consecutive cases. Anesthesiology (2005) 1.88
Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2005) 1.82
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest (2004) 1.72
Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med (2008) 1.71
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 1.71
Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol (2008) 1.69
Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest (2012) 1.68
Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med (2015) 1.62
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed) (2016) 1.61
Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant (2007) 1.58
Potts shunt in children with idiopathic pulmonary arterial hypertension: long-term results. Ann Thorac Surg (2012) 1.54
IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Ann Rheum Dis (2011) 1.53
Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2007) 1.52
Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med (2010) 1.50
Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. Chest (2010) 1.48
Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2003) 1.46
Pre-implantation genetic diagnosis in pulmonary arterial hypertension due to BMPR2 mutation. Eur Respir J (2012) 1.45
Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) (2008) 1.43
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol (2007) 1.42
Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. AJR Am J Roentgenol (2004) 1.41
Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum (2008) 1.40
Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med (2004) 1.40
Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. Chest (2013) 1.39
Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med (2002) 1.38
Sildenafil for pulmonary arterial hypertension: still waiting for evidence. Am J Respir Crit Care Med (2004) 1.38
Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum (2011) 1.35
Diagnostic strategy for patients with suspected pulmonary embolism: a prospective multicentre outcome study. Lancet (2002) 1.32
Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest (2006) 1.29
HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS (2010) 1.27
Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res (2010) 1.19
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest (2008) 1.16
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther (2009) 1.10
Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol (2010) 1.08
Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol (2011) 1.08
Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.08
Pulmonary veno-occlusive disease: recent progress and current challenges. Respir Med (2010) 1.06
Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. Proc Am Thorac Soc (2006) 1.05
Out-of-proportion pulmonary hypertension and heart failure with preserved ejection fraction. Respiration (2012) 1.03
Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J (2010) 1.01
Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr (2002) 1.01
Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) (2007) 0.97
Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis (2006) 0.96
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) (2009) 0.96
Increased oxidative stress and severe arterial remodeling induced by permanent high-flow challenge in experimental pulmonary hypertension. Respir Res (2011) 0.95
Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 0.94
Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin Pharmacother (2005) 0.93
Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc (2006) 0.93
Diagnostic value of D-dimer in patients with suspected pulmonary embolism: results from a multicentre outcome study. Thromb Res (2006) 0.92
Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. Rheumatology (Oxford) (2010) 0.92
Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum (2011) 0.91
Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. Eur J Cardiothorac Surg (2010) 0.91
Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J (2011) 0.90
Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant (2011) 0.90
Pulmonary hypertension in patients with neurofibromatosis type I. Medicine (Baltimore) (2011) 0.90
Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. Semin Respir Crit Care Med (2009) 0.90
Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J (2012) 0.90
Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Curr Opin Pulm Med (2010) 0.89
An extreme consequence of splenectomy in dehydrated hereditary stomatocytosis: gradual thrombo-embolic pulmonary hypertension and lung-heart transplantation. Hemoglobin (2003) 0.88
Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis (2008) 0.88
Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. AIDS (2005) 0.87
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment. Expert Opin Drug Metab Toxicol (2013) 0.85
Pulmonary arterial hypertension and its association with HIV infection: an overview. AIDS (2008) 0.85
Pulmonary hypertension associated with benfluorex exposure. Eur Respir J (2012) 0.85
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J (2012) 0.85
EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism. Eur Respir J (2012) 0.85
Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev (2013) 0.84
Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. Chest (2011) 0.84
Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respir Med (2010) 0.84
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J (2012) 0.83
Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest (2002) 0.83
Primary pulmonary hypertension: Current therapy. Prog Cardiovasc Dis (2002) 0.82
Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother (2011) 0.82
Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Curr Opin Pulm Med (2010) 0.81
Pulmonary arterial hypertension: bridging the present to the future. Eur Respir Rev (2012) 0.81
N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. Respir Res (2014) 0.81